School of Life & Health Sciences Aston University Aston Triangle Birmingham B4 7ET UK
email: M.J.Tisdale@aston.ac.uk telephone: +44 (0) 121 204 4021 fax: +44 (0) 121 204 3743
Chronic and Communicable Conditions
Aston Research Centre for Healthy Ageing (ARCHA)
I joined the Cancer Research Campaign Experimental Chemotherapy Group in the Department of Pharmacy at Aston University as Senior Research Fellow in October 1980. Prior to that I spent 8 years as Lecturer in the Department of Biochemistry at St Thomas’s Hospital Medical School, University of London, one year as Scientific Officer at Rothamstead Experimental Station, Harpenden and one year as MRC Fellow at the Institute of Cancer Research.
• 1989–date: Professor of Cancer Biochemistry, Aston University • 1992-95: Head of Department, Pharmaceutical and Biological Sciences, Aston University • 1984-89: Reader, Department of Pharmaceutical Sciences, Aston University • 1981-84: Senior Research Fellow, CRC Experimental Chemotherapy Group, Aston University • 1972-81: Lecturer Department of Biochemistry, St Thomas’s Medical School • 1971-72: Scientific Officer, Rothamstead Experimental Station • 1970-71: MRC Fellow, Institute of Cancer Research
Mainly related to cancer causation, biology treatment and associated conditions e.g. cachexia.
Modules: PH3 CM1, PH1 CM1, BY3 CM1, BY1 CM1, BY2 BD1, PH3 MC1
Cancer cachexia, mechanism and treatment. Treatment of obesity and type 2 diabetes.
Specifically:
• Signal transduction pathways involved in muscle catabolism by proteolysis-inducing factor (PIF) • Cloning and sequencing of cellular receptor for PIF • Cloning and expression of PIF • Investigation of antibodies to the PIF receptor as anticachectic agents • Action of eicosapentaenoic acid (EPA) in preventing muscle catabolism by PIF • Role of EPA in attenuating muscle catabolism in catabolic states other than cancer cachexia • Clinical evaluation of EPA in the treatment of cancer cachexia
Awarding Body
Title of Project
Amount (£)
Dates
Halsa Pharmaceuticals
Evaluation of zinc-alpha 2-glycoprotein for the treatment of obesity
220,000
2008-2010
Bioneris
Anticachectic activity of a novel agent
135,000
2006-2009
Ross Products Division
Effect of ingredients in an animal model of cachexia
490,536
2002-2008
British Technology Group
Studies on the PIF receptor
74,986
2005
Novartis Medical Nutrition
Investigation into the mechanism for depression of protein synthesis in cancer
152,404
2004-2007
Ark Therapeutics
To determine whether angiotensin II has a direct effect on muscle protein degradation
142, 528
2003-2005
Bayer Healthcare
The potential therapeutic use of zinc-alpha2-glcyoprotein for obesity and type II diabetes
196,868
2002-2004
Lustgarten Foundation
Cloning and expression of a muscle receptor for a cancer-cachectic factor
50,655
2003
Novartis Consumer Health
Studies on cancer cachexia
131,964
2003-2004
Browser does not support script.